Lack of Gender Equity in Academic Rheumatology

Save

Evidence on gender equity in academic rheumatology in Europe is currently limited. This knowledge gap has a direct effect on the ability of professional bodies to improve gender equity. To address this, EULAR designed a study using web-based surveys to collect information; here are the results.

Excessive Alcohol-Related Deaths in US Adults

Save

Alcohol consumption is a leading preventable cause of death in the U.S.  A JAMA cross-sectional study suggests that between 2015 and 2019, an estimated 1 in 8 total deaths among U.S. adults ages 20 to 64 were attributable to excessive alcohol use, including 1 in 5 deaths among adults ages 20 to 49. 

EMA Crack Down on JAK Inhibitors

Save

The European Medicines Agency’s (EMA's) safety committee (PRAC) has issued a recommendation that the use of oral JAK inhibitors (tofacitinib, baricitinib, upadacitinib and filgotinib) be limited to certain at-risk patients unless no other suitable treatment alternatives are available.

Infections & Lupus (10.28.2022)

Save

Dr. Jack Cush discusses the news and journal reports from the past week on RheumNow. This week more lupus nephritis, more drug induced lupus and more lupus infections that may kill. 

Growing Confidence in Biosimilars?

Save

Today, Cardinal Health released its third edition of Rheumatology Insights, a research report based on surveys with more than 100 rheumatologists nationwide that focuses on key trends

Infection: a Leading Cause of Death in Lupus

Save

 Analysis of a national database of hospital discharges from Spain shows that infections accounted for 25% of lupus deaths, making infection the most common cause of death in SLE.

Update to Axial Spondyloarthritis Guidance

Save

EULAR and the Assessment of SpondyloArthritis International Society (ASAS) has updated their guidance on axial spondyloarthritis (axSpA) management.

New ACR/EULAR Guideline Expands RA Remission Definition

Save

Newly released guidance for defining remission in rheumatoid arthritis (RA) is expected to increase the number of patients achieving it while maintaining its ability to predict good objective outcomes.

Increasing Prevalence of RA, PsA and AS in the UK

Save

Electronic health record (EHR) database analysis from the United Kingdom suggests an increasing number of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritits (SpA) patients in England.

Increasing Risk of Lupus Nephritis

Save

Population based study from Minnesota shows that the incidence of lupus nephritis (LN) in the US has increased in the last four decades and that LN patients have poorer outcomes with high rates of ESRD and mortality rates six times that of the general population.

2022 ASAS-EULAR Guidelines for Axial Spondyloarthritis

Save

Assessment of SpondyloArthritis international Society (ASAS) and EULAR have published their 2022 update and recommendations for the management of axial spondyloarthritis (axSpA).

FDA Approves Upadacitinib for Non-Radiographic Axial Spondyloarthritis

Save

On Friday October 21st the U.S. Food and Drug Administration approved upadacitinib (Rinvoq) for the treatment of active non-radiographic axial spondyloarthritis in patients with objective signs of inflammation who have had an inadequate response or intolerance to tumor necrosis factor blocker therapy.